ALK and non-small cell lung carcinoma: The progressive accumulation of on-target mutations in adult patients with ALK fusion-positive NSCLC receiving successive generations of ALK inhibitor13,16 has led to the clinical conundrum of which drug to initiate in frontline therapy.